Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMX103 (Zilxi) in facial papulopustular rosacea
NCT03142451Phase 3Completed
- Sponsor
- Vyne Therapeutics
- Start
- Jun 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minocycline in papulopustular rosacea (2 arms), sponsored by Vyne Therapeutics. Primary endpoints: Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 and Percentage of Participants Achieving Investigator Global Assessments (IGA) Treatment Success at Week 12. Started Jun 2017; status: completed.
02
Drugs
minocycline
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT03142451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142451.